Bilibili Inc vs Recursion Pharmaceuticals Inc — how do they compare? Bilibili Inc trades at $17.4 (market cap $7.65B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Bilibili Inc is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| BILI | RXRX | |
|---|---|---|
Market Cap | $7.65B | $1.81B |
Sector | Media | Health |
52-Week High | $35.92 | $6.79 |
52-Week Low | $15.96 | $2.84 |
Enterprise Value | $5.49B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →